Advertisement
Advertisement

SoftBank to Lead Nearly $1.2 Billion Investment in Diagnostics Firm Invitae

By:
Reuters
Updated: Apr 5, 2021, 13:05 UTC

(Reuters) -Invitae Corp said on Monday a group of investors including SoftBank Group Corp will invest $1.15 billion in the U.S. genetic diagnostics company.

SoftBank Corp's logo is pictured at a news

It said the investment, to be used for its growth initiatives, will be in convertible senior notes, which will bear 1.5% interest per year.

The company said the notes will have an initial conversion price of $43.18 per share of its common stock, representing a premium of 10.2% to Invitae’s closing price on Friday.

Earlier this year, SoftBank invested $900 million in gene sequencing firm Pacific Biosciences of California Inc.

San Francisco-based Invitae offers genetic testing services for a range of diseases, including skin and eye conditions, cancers as well as reproductive health in and outside the United States.

Shares of the company, which started operations in 2010, have more than tripled in the past twelve months, giving it a market valuation of $7.7 billion.

J. Wood Capital Advisors LLC and Perella Weinberg Partners LP were financial advisers to Invitae on the transaction.

(Reporting by Amruta Khandekar in Bengaluru; Editing by Shinjini Ganguli)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:

Did you find this article useful?

Advertisement